Welcome to our dedicated page for Processa Pharmaceuticals SEC filings (Ticker: PCSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Processa Pharmaceuticals, Inc. (PCSA) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage pharmaceutical company listed on the Nasdaq Capital Market, Processa uses filings such as Forms 8-K, proxy statements, and registration statements to report material events related to its capital structure, shareholder votes, financing transactions, and listing status.
Recent Form 8-K filings detail key corporate actions, including a 1-for-25 reverse stock split of issued and outstanding common shares implemented through a Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation. The filings explain that the reverse split became effective in December 2025, that the par value of the common stock was unchanged, and that the stock continued to trade on Nasdaq under the PCSA symbol with a new CUSIP number. Earlier 8-K and 8-K/A filings describe shareholder approval of amendments to increase authorized common shares from 100,000,000 to 1,000,000,000 and to authorize a reverse stock split within a specified ratio range.
Filings also address Nasdaq listing compliance. In an 8-K dated August 8, 2025, Processa reported receiving a second 180-day grace period from Nasdaq to regain compliance with the $1.00 minimum bid price requirement, and noted that it might implement a reverse stock split to cure the deficiency. Additional 8-Ks and the definitive proxy statement (DEF 14A) provide details on special meetings of stockholders, quorum issues, adjournments, and final voting results on proposals related to authorized share increases, the reverse stock split, and amendments to the company’s omnibus incentive plan.
Capital-raising activities are also documented in SEC filings. For example, an 8-K filed in June 2025 describes the pricing of a public offering of common stock (and pre-funded warrants in lieu thereof) with associated common warrants, stating that net proceeds are intended to support the Phase 2 NGC-Cap trial and general corporate purposes. Another 8-K filed in August 2025 outlines a private placement securities purchase agreement with an accredited investor, including gross proceeds, use of proceeds for general corporate purposes, and placement agent compensation.
On Stock Titan, these filings are supplemented by AI-powered summaries that highlight the most important points from each document, such as changes to authorized shares, reverse stock split terms, Nasdaq notices, and financing structures. Users can quickly see how each filing affects Processa’s capital structure, listing status, and governance, while still having the option to review the full text of the original SEC documents. As additional quarterly and annual reports (Forms 10-Q and 10-K), proxy statements, and Form 4 insider transaction reports become available on EDGAR, they are incorporated into this page with real-time updates and plain-language explanations.
Processa Pharmaceuticals director and Pres. Research & Development David Young reported an open-market purchase of 1,545 shares of common stock at $2.97 per share on April 15, 2026. After this trade, he holds 12,107 shares directly, plus indirect holdings of 1,242 shares via the Young-Plaisance Revocable Trust, 432 shares via family entities, and 742 shares via CorLyst, LLC.
Processa Pharmaceuticals, Inc. Chief Executive Officer George K. Ng bought additional company stock in the open market. He purchased 1,843 shares of common stock at $2.97 per share, bringing his directly held position to 5,492 shares. The filing also lists indirect holdings of 3,488 shares held under "George Ng IRRA FOB George Ng" and 800 shares held through the "Ng Cha Family Trust," showing both personal and related-entity ownership of Processa common stock.
Processa Pharmaceuticals, Inc. Chief Business - Strategy Officer Patrick Lin bought common stock in the open market. On April 15, 2026, he purchased 1,369 shares of Processa common stock at $2.97 per share. After this transaction, he directly holds 4,725 shares and indirectly holds 1,740 shares through the Lin Family Trust dated February 4, 2024.
Processa Pharmaceuticals Chief Administrative Officer Wendy Guy purchased 1,583 shares of common stock in an open-market transaction at $2.97 per share. After this purchase, she holds 4,693 shares directly and 333 shares indirectly through CorLyst, LLC.
Processa Pharmaceuticals, Inc. Chief Development Officer Sian Bigora reported an open-market purchase of 1,799 shares of common stock at $2.97 per share on April 15, 2026. Following this trade, Bigora directly holds 5,510 common shares and has indirect ownership of 267 shares through CorLyst, LLC.
Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of company shares. On April 15, 2026, he bought 1,984 shares of Common Stock at $2.97 per share in a direct ownership transaction, bringing his directly held stake to 4,308 shares.
Processa Pharmaceuticals director Neal James R reported an open-market purchase of the company’s Common Stock. On March 31, 2026, he bought 789 shares at a price of $2.535 per share, bringing his direct ownership to 818 shares after the transaction, indicating a small, routine insider buy.
Processa Pharmaceuticals Pres. of Research & Development David Young bought 1,810 shares of common stock in an open-market purchase at $2.535 per share. After this trade, he directly holds 10,562 shares and has additional indirect holdings through the Young-Plaisance Revocable Trust, family entities, and CorLyst, LLC.
Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of company stock. He bought 2,324 shares of Common Stock at a price of $2.535 per share on March 31, 2026, and now directly holds 2,324 shares following this transaction.
Processa Pharmaceuticals director Geraldine Pannu reported an open-market purchase of Common Stock. On March 31, 2026, she bought 2,072 shares at $2.535 per share, bringing her direct holdings to 2,188 shares. This was a straightforward open-market buy with no derivatives involved.